Category Archives: Stem Cell Therapy

The stem-cell research community reels after Yoshiki Sasai, a famous name in regenerative medicine, is found dead on August 5

Yoshiki Sasai. Credit: Nick Higgins

Scientists around the world are struggling to get to grips with the loss of one of the brightest stars in stem-cell science. Yoshiki Sasai of the RIKEN Center for Developmental Biology (CDB) in Kobe brought excitement and rigour to the field but died yesteday, August 5, aged 52. The reasons for Sasais apparent suicide are still not clear but a scandal swirling about two stem-cell papers published inNaturein January had wreaked havoc on his career.

Dr. Sasai was a rigorous and innovative scientist and his loss will be deeply felt, saysJanet Rossantat the Hospital for Sick Children in Toronto, Canada, a former head of the International Society for Stem Cell Research. His most important contributions to the stem-cell field came from his background in developmental biology.

Sasais research spanned developmental biology, stem cells, organogenesis and tissue engineering. His success was built on his painstaking efforts to understand exactly which factors needed to be added or removed to cell cultures to guide embryonic stem cells as they differentiated to mature cell types,especially neuronal cells.

He sees things that others dont see,Eddy De Robertistold Naturein a 2012 interview. De Robertis, a developmental biologist at the University of California, Los Angeles, who supervised Sasais postdoctoral work in the mid 1990s, recalled Sasai once retyping a manuscript lost in a computer from memory with word-for-word perfection. Id never seen anything like that, he said.

Lab-grown cortex One of Sasais innovations was thediscovery in 2007of a pharmacological compound that kept embryonic stem cells from dying when separated from each other. Previously, embryonic stem cells had to be manually cut with a cumbersome method and transferred as partial colonies, which resulted in experimental variation. His paper solved that overnight, saysLuc Leynsof the Vrije Universiteit in Brussels.

But Sasai's show-stoppers came shortly after that. Based on his success in differentiating neurons, Sasai started mimicking embryonic development with such fidelity that his cells would organize themselves into three-dimensional structures, including agoblet-shaped clump of retinal tissue known as an optic cupandintricate layers of tissue that resembled a cerebral cortex.

Both these discoveriesopened the field ofin vitrobrain organogenesis. Finally, we have easy access to the developing brain without having to micro dissect embryos, says Leyns. Leyns says he uses Sasais papers to show masters students how a modern scientific discovery is made and progressively built-up to a climax.

Sasais work was inspirational, says Pete Coffey of University College London, where Sasai presented the optical cup research last November. The clarity of his presentation, the excitement and post lecture discussions with fellows and students are still discussed today. He had a major impact on my group, says Coffey. Sasais research will probably contribute to treatments for various disorders, such as macular degeneration. His findings galvanized the ophthalmology community in truly developing a cell therapy for blinding disorders, says Coffey.

Read this article:
Star Scientist Embroiled in Controversy Found Dead in Apparent Suicide

MONDAY, Aug. 4, 2014 (HealthDay News) -- Could stem cell injections help rejuvenate your face or body? Probably not, plastic surgery experts say, but ads for these types of bogus procedures abound on the Internet.

"Stem cells offer tremendous potential, but the marketplace is saturated with unsubstantiated and sometimes fraudulent claims that may place patients at risk," a team led by Dr. Michael Longaker, of Stanford University Medical Center, wrote in a review published in the August issue of Plastic and Reconstructive Surgery.

The experts say consumers need to be wary of advertisements promoting the benefits of "minimally invasive, stem cell-based rejuvenation procedures." Claims for stem cell procedures for facelifts, breast augmentation and vaginal rejuvenation are not only unsubstantiated, but also risky, Longaker's team said.

They note that, to date, the U.S. Food and Drug Administration has approved only one cosmetic stem cell procedure designed to treat fine facial wrinkles. And since that single procedure was approved, the product involved has been monitored extensively.

Overall, cosmetic stem cell procedures have not undergone significant scientific scrutiny, the Stanford team said. The risks associated with stem cell and tissue processing have not been closely examined. The effects of aging on stem cells are also not well established, the researchers explained.

To investigate concerning claims being made about cosmetic stem cell procedures, the researchers performed a basic Internet search. They found the most common result was "stem cell facelifts." Most of the procedures used stem cells isolated from fat but did not provide details on the quality of the stem cells.

More than 100 clinical trials are currently evaluating stem cells derived from fat, but few are focusing on cosmetic treatments. The researchers cautioned that the products used in these cosmetic procedures likely involves additional types of cells unless they utilized sophisticated cell-sorting techniques.

Many blood plasma-enriched "platelet protein treatments" are also incorrectly advertised as stem cell therapy, the study's authors noted.

Meanwhile, there is only minimal evidence that cosmetic stem cell procedures have any anti-aging effects, the researchers said. They warn that stem cell facelifts may actually be "lipo-filling" procedures -- fat injections with no prolonged anti-aging effect.

Although stem cells do hold potential for cosmetic procedures in years to come, today's advertising claims for these procedures are going beyond any scientific evidence on safety and effectiveness, the researchers conclude.

See original here:
Most cosmetic procedures based on stem cells are bogus

Heal Interstitial Cystitis with Stem Cell Therapy
via YouTube Capture.

By: Minecraft madness and mayhem

The rest is here:
Heal Interstitial Cystitis with Stem Cell Therapy - Video

Stem cell agency President C. Randal Mills (left) and Chairman of the Board Jonathan Thomas.

Responding to his predecessor's ethically controversial departure, the president and chief executive of California's stem cell agency said Thursday he is taking legal steps to minimize conflicts of interests with those who have business before the agency.

C. Randal Mills said he will not take a job with any company funded by the California Institute for Regenerative Medicine for one year after he departs the agency. In addition, he also will not accept gifts or travel payments from any company, institution or person who gets agency funding.

Mills' action, announced at the agency's meeting in Millbrae, will be enforced with a legal agreement he will sign. His action comes less than a month after he replaced Alan Trounson as the agency chief. One week after his departure, CIRM-funded StemCells Inc. announced it had appointed Trounson to its board. StemCells Inc. had received an award of nearly $20 million from the agency to develop a therapy for Alzheimers disease.

While Trounson's appointment wasn't illegal, critics said it was unseemly for him to join a company that had received agency funding so soon after he left CIRM. An ethical controversy could harm the agency's chances of getting more funding from California voters, who gave the agency $3 billion with the passage of Proposition 71 in 2004.

Mills said the new rules apply only to himself, because of his central role at CIRM.

"This specifically addresses an issue where an individual in an organization has a disproportionate amount of power, and I want to make sure it's known that power will not be abused," Mills said.

Mills made the right decision, said Jeanne Loring, a CIRM-funded stem cell researcher at The Scripps Research Institute.

"There's a difference between what is legal and what is ethical," said Loring, who attended the meeting. "And he's going to be pushing the needle a lot more toward the ethical side without worrying whether he can get away with stuff."

John Simpson of Santa Monica-based Consumer Watchdog, who has often criticized CIRM for conflicts of interest, also praised the decision.

See the article here:
Stem cell agency tightens ethics rules

La Jolla, CA (PRWEB) July 23, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study for Parkinsons disease. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with degenerative diseases.

This clinical study makes stem cell therapy accessible to the millions of individuals currently living with Parkinsons disease. The protocol used in these stem cell treatments is unique to StemGenex, having the possibility of being more effective than other stem cell treatments currently available. StemGenex has developed a multiple administration protocol for patients suffering from Parkinsons disease which includes targeted methods of stem cell delivery. Among these methods is a novel approach for delivering stem cells past the blood brain barrier an issue most stem cell treatments have been challenged by.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, As is the case with most neurodegenerative conditions, there are few available drugs to treat Parkinsons disease. The handful of drugs that are available can only ameliorate symptoms and unfortunately, prolonged usage can create terrible side-effects. Further, these drugs do not halt disease progression or aid in the repair of established damage. Our goal is to provide regenerative medicine applications that address these critical issues. The study we are conducting is designed to provide us with a large amount of rigorously collected data so that we can better understand the clinical benefit of Parkinsons patients treated with stem cells.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell therapy. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex stated, Parkinson's disease affects a very small part of the brain but anyone suffering with this disease understands the negative impact on his or her life is very big, actually, enormous. Over the last several years we have observed significant improvement in the symptoms of Parkinsons patients through stem cell treatment. We are determined to be part of the solution and are eager to document and publish our findings in the next few years.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Parkinsons disease and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com.

Excerpt from:
StemGenex Gives Hope to Parkinsons Patients through New Stem Cell Clinical Study

Written by The Edge Wednesday, 23 July 2014 17:20

Cordlife Group said it has partnered China Cord Blood Corporation, the leading provider of cord blood collection and stem-cell storage services on the Mainland, today announced that the two companies have joined forces in assisting patients in China, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy.

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current Chinese government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorised as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

More:
Cordlife Group partners China Cord Blood Corporation to help Asian patients

Brescia hospital ordered to let discredited therapy resume

(ANSA) - Brescia, July 22 - A controversial stem-cell treatment was administered to a child suffering from muscular dystrophy at a hospital in northern Italy on Tuesday despite having been discredited. The Stamina treatment was administered on the orders of a Sicilian court after the hospital in Brescia decided to suspend the procedure on the boy suffering from Duchenne muscula dystrophy because it had been called into doubt. The child "will remain in observation for a few hours and we will carry out a few tests," said Giuseppe Morfino, the court-appointed doctor leading the external team that performed the treatment. Morfino added that the atmosphere at the hospital had been cooperative. The credibility of the Stamina treatment, which involves extracting bone-marrow stem cells from a patient, supposedly turning them into neurons by exposing them to retinoic acid for two hours, and injecting them back into the patient, has long been suspect, and last autumn the health ministry ruled that the Stamina Foundation would no longer be allowed to test the treatment on humans. The foundation was also stripped of its non-profit status after a study found its treatment was "ignorant of stem-cell biology". Recent investigations have shown risks of the treatment range from nausea to cancer, and reported that as many as one-quarter of all patients treated have experienced "adverse effects". In April, after study results became known, hospitals in Italy announced they had suspended the stem-cell treatment program. However, some local judges have ruled in favor of its application, despite the bans, amid heavy pressure from advocates and the families of patients.

See the original post:
Controversial Staminia treatment carried out on sick boy